



(51) International Patent Classification:

A61K 9/14 (2006.01) A61K 31/4743 (2006.01)
A61K 9/16 (2006.01)

(21) International Application Number:

PCT/US2011/039430

(22) International Filing Date:

7 June 2011 (07.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/352,862 9 June 2010 (09.06.2010) US

(71) Applicant (for all designated States except US): **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MILLER, Jonathan** [US/US]; 1228 Meade Drive, Lindenhurst, Illinois 60046 (US). **GOKHALE, Rajeev** [US/US]; 2250 Hanlon Road, Libertyville, Illinois 60048 (US). **SCHMITT, Eric, A.** [US/US]; 319 Evergreen Court, Libertyville, Illinois 60048 (US). **GAO, Yi** [US/US]; 210 East Baltusrol, Vernon Hills, Illinois 60061 (US). **LAFOUNTAIN, Justin** [US/US]; 659 W. Randolph #913, Chicago, Illinois 60661 (US). **DIAS, Lloyd** [US/US]; 7439 Korb Drive, Gurnee, Illinois 60031 (US).

(74) Agents: **STEELE, Susan, L.** et al.; Abbott Laboratories, 100 Abbott Park Road, AP6A-1/D0377, Abbott Park, Illinois 60064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

5 July 2012

(54) Title: SOLID DISPERSIONS CONTAINING KINASE INHIBITORS

(57) Abstract: A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.

